Literature DB >> 16174232

Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis.

G Mangili1, G Aletti, L Frigerio, M Franchi, N Panacci, R Viganò, P DE Marzi, F Zanetto, A Ferrari.   

Abstract

Bowel obstruction is the most common complication in patients with ovarian cancer. Management of this situation is controversial. The aim of our retrospective study was to determine the best approach for managing bowel obstruction in recurrent ovarian cancer. A retrospective analysis of data on 47 patients with intestinal obstruction by ovarian cancer was performed. Twenty-seven patients were submitted to surgery, with 21 intestinal procedures performed, 2 gastrostomy tubes placed, and 4 patients deemed inoperable. Twenty patients were managed medically with Octreotide (mean dosage of 0.48 mg/day), of which 1 patient required a nasogastric tube. Age, performance status, diagnosis of tumor to occlusion time, obstruction site, previous chemotherapy or radiotherapy, presence of ascites, or palpable masses were the variables analyzed. Student's t-test and Pearson chi-square test were used to compare the two different groups of treatment (surgical vs medical therapy). Disease-free-survival curves were plotted according to the Kaplan-Meier method and analyzed by the log-rank test. Cox's proportional hazards model was used for multivariate analysis. Values less than or equal to 0.05 were considered significant. The mean age of the patients was 58.7 years. Perioperative mortality and morbidity were both 22%. All patients died with minimal distress. Performance status results were significantly different between the patients submitted to surgery and patients treated with Octreotide (P= 0.03). No significant differences were found in the other variables analyzed. In multivariate analysis, only type of treatment emerges as a strong predictor of poor outcome (P < 0.001). Both surgery and Octreotide therapy are able to control distressing symptoms in end-stage ovarian cancer. Survival was significantly longer in the surgical group, and surgical palliation should be considered first in patients with good performance status.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174232     DOI: 10.1111/j.1525-1438.2005.00144.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  19 in total

Review 1.  [Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients : a systematic literature review].

Authors:  C Klein; S Stiel; J Bükki; C Ostgathe
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

2.  Bowel obstruction in elderly ovarian cancer patients: a population-based study.

Authors:  Stephen J Mooney; Megan Winner; Dawn L Hershman; Jason D Wright; Daniel L Feingold; John D Allendorf; Alfred I Neugut
Journal:  Gynecol Oncol       Date:  2012-12-26       Impact factor: 5.482

Review 3.  Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  Sarah E Cousins; Emma Tempest; David J Feuer
Journal:  Cochrane Database Syst Rev       Date:  2016-01-04

4.  Outcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy.

Authors:  Tomoko Goto; Masashi Takano; Tadashi Aoyama; Morikazu Miyamoto; Akio Watanabe; Masafumi Kato; Naoki Sasaki; Junko Hirata; Hidenori Sasa; Kenichi Furuya
Journal:  Oncol Lett       Date:  2012-07-30       Impact factor: 2.967

Review 5.  Palliative surgery versus medical management for bowel obstruction in ovarian cancer.

Authors:  Ali Kucukmetin; Raj Naik; Khadra Galaal; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

6.  Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites.

Authors:  Colette Shaw; Roland L Bassett; Patricia S Fox; Kathleen M Schmeler; Michael J Overman; Michael J Wallace; Sanjay Gupta; Alda Tam
Journal:  Ann Surg Oncol       Date:  2012-09-11       Impact factor: 5.344

7.  Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.

Authors:  Koshi Kumagai; Yoshiro Saikawa; Kazumasa Fukuda; Ryo Ito; Takahiro Igarashi; Shinichi Tsuwano; Rieko Nakamura; Tsunehiro Takahashi; Hiroya Takeuchi; Yuko Kitagawa
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

Review 8.  Current concepts in malignant bowel obstruction management.

Authors:  Eric Roeland; Charles F von Gunten
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

9.  Management and outcomes of bowel obstruction in patients with stage IV colon cancer: a population-based cohort study.

Authors:  Megan Winner; Stephen J Mooney; Dawn L Hershman; Daniel L Feingold; John D Allendorf; Jason D Wright; Alfred I Neugut
Journal:  Dis Colon Rectum       Date:  2013-07       Impact factor: 4.585

Review 10.  Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review.

Authors:  Terrah J Paul Olson; Carolyn Pinkerton; Karen J Brasel; Margaret L Schwarze
Journal:  JAMA Surg       Date:  2014-04       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.